好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Double Blind, Placebo Controlled Trial of Atorvastatin in Combination with Subcutaneous Interferon Beta 1a in Persons with Multiple Sclerosis
MS and Related Diseases
(-)
005
Authors/Disclosures
Gary Birnbaum, MD, FAAN No disclosure on file
Irfan M. Altafullah, MD (Minneapolis Clinic of Neurology) No disclosure on file
Binod Wagle, MD, FAAN (Providence Medical Group) Dr. Wagle has nothing to disclose.
Anthony Reder, MD (University of Chicago) The institution of Dr. Reder has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for genentech. Dr. Reder has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for serono. Dr. Reder has received personal compensation in the range of $500-$4,999 for serving as a Consultant for sanofi. The institution of Dr. Reder has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for bms. Dr. Reder has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NK max. Dr. Reder has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for genentech. Dr. Reder has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for medlink. The institution of Dr. Reder has received research support from genentech. The institution of Dr. Reder has received research support from biogen. The institution of Dr. Reder has received research support from serono. The institution of Dr. Reder has received research support from novartis.